{"filing":{"accession_number":"0001140361-26-033749","cik":"0001472091","ticker":"PDSB","company_name":"PDS Biotechnology Corp","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-13","primary_document":"ef20080681_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126033749/ef20080681_8k.htm"},"events":[{"id":28577,"run_id":26148,"accession_number":"0001140361-26-033749","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective September 12, 2026. While the filing also discloses interim appointments of Janetta Trochimiuk and Frank Bedu-Addo to fill these roles, the principal disclosed action centers on the departure of the CFO. The resignation of a named executive officer in a financial leadership role is material to investors, though the interim appointments and lack of disagreement statement reduce the severity somewhat.","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30569,"accession_number":"0001140361-26-033749","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective September 12, 2026. While the filing also discloses interim appointments of Janetta Trochimiuk and Frank Bedu-Addo to fill these roles, the principal disclosed action centers on the departure of the CFO. The resignation of a named executive officer in a financial leadership role is material to investors, though the interim appointments and lack of disagreement statement reduce the severity somewhat.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:53:37.016709+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30569,"accession_number":"0001140361-26-033749","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective September 12, 2026. While the filing also discloses interim appointments of Janetta Trochimiuk and Frank Bedu-Addo to fill these roles, the principal disclosed action centers on the departure of the CFO. The resignation of a named executive officer in a financial leadership role is material to investors, though the interim appointments and lack of disagreement statement reduce the severity somewhat.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:53:37.016709+00:00","company_name":"PDS Biotechnology Corp","ticker":"PDSB","filing_date":"2026-08-19"}]}